NX PharmaGen
NX PharmaGen acquires, develops, and monetizes mature clinical-stage breakthrough technologies.
Launch date
Employees
Market cap
-
Enterprise valuation
AUD11—17m (Dealroom.co estimates Mar 2015.)
Louisville Kentucky (HQ)
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
| N/A | $3.5m | Angel | |
| N/A | $773k | Debt | |
| N/A | $1.8m | Early VC | |
| N/A | $486k | Early VC | |
* | N/A | $590k | Debt |
| Total Funding | AUD8.9m | ||
Recent News about NX PharmaGen
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.